Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Serina Therapeutics Inc (SER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SER (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.81% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 52.59M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 3.81 - 10.28 | Updated Date 08/29/2025 |
52 Weeks Range 3.81 - 10.28 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.92 |
Earnings Date
Report Date 2025-08-04 | When Before Market | Estimate -0.425 | Actual -0.66 |
Profitability
Profit Margin - | Operating Margin (TTM) -4280.77% |
Management Effectiveness
Return on Assets (TTM) -132.37% | Return on Equity (TTM) -485.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 51669516 | Price to Sales(TTM) 404.5 |
Enterprise Value 51669516 | Price to Sales(TTM) 404.5 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 37.36 | Shares Outstanding 10250600 | Shares Floating 3076099 |
Shares Outstanding 10250600 | Shares Floating 3076099 | ||
Percent Insiders 62.09 | Percent Institutions 4.03 |
Upturn AI SWOT
Serina Therapeutics Inc
Company Overview
History and Background
Serina Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics utilizing its proprietary POZ platform to address unmet medical needs. Founded to advance polymer therapeutics, Serina has evolved to focus on areas of significant therapeutic potential. Specific founding year and detailed milestones are not publicly available in common financial resources but known to be founded sometime in the 2006-2012 range.
Core Business Areas
- Drug Development: Focuses on developing and commercializing novel therapeutics for pain management, anti-inflammatory, oncology and pulmonary disease. Serina has partnered with multiple universities to create several new drugs.
- POZ Platform Technology: Serina's core platform technology that underpins their drug development efforts, enabling targeted drug delivery and improved therapeutic efficacy.
Leadership and Structure
Information about leadership team is available on Serina's website, typically including a CEO, CFO, and heads of research and development. Organizational structure involves research, clinical development, and administrative departments.
Top Products and Market Share
Key Offerings
- ST-009: A pain management drug candidate developed by the company that is being evaluated for its efficacy. Market share data is unavailable because this drug is in clinical stages. Key competitors in pain management include companies with marketed opioids and non-opioid pain relievers (e.g., Pfizer, Johnson & Johnson, Eli Lilly). Serina is targeting a more focused and efficacious candidate.
- Other Candidates: Serina also lists other drugs in their pipeline and at various stages of development. Market share is unavailable because these are still under development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D spending, stringent regulatory requirements, and intense competition. It is driven by innovation in drug development and the increasing prevalence of diseases.
Positioning
Serina Therapeutics is positioned as a specialty pharmaceutical company focused on utilizing its POZ platform to develop novel therapeutics. Their competitive advantage lies in their proprietary technology and targeted drug delivery capabilities.
Total Addressable Market (TAM)
TAM varies depending on the specific indication targeted by Serina's drug candidates. Pain management, oncology, and pulmonary diseases represent substantial market opportunities with multi-billion dollar valuations. Serina's positioning is to capture a share of these markets with differentiated products.
Upturn SWOT Analysis
Strengths
- Proprietary POZ platform technology
- Novel drug candidates in development
- Experienced management team
- Partnerships with universities
Weaknesses
- Limited financial resources
- Early-stage development risk
- Dependence on clinical trial success
- Lack of marketed products
Opportunities
- Advancement of drug candidates through clinical trials
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Potential for FDA approval and commercialization
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- PFE
- JNJ
- LLY
Competitive Landscape
Serina faces significant competition from established pharmaceutical companies with larger R&D budgets and marketed products. Serina's advantage lies in its proprietary technology and targeted drug delivery capabilities, allowing the company to pursue niche opportunities and differentiated products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth would be reflected in the advancement of drug candidates through clinical trials and securing funding.
Future Projections: Future growth is highly dependent on successful clinical trial outcomes, regulatory approvals, and potential commercial partnerships. Analyst estimates are contingent upon these factors.
Recent Initiatives: Recent initiatives would involve the progress of clinical trials, securing financing, and expanding their IP portfolio.
Summary
Serina Therapeutics is a development-stage biopharmaceutical company with a promising POZ platform. Its strength lies in its innovative technology and novel drug candidates, while its weaknesses are limited financial resources and reliance on clinical trial success. Serina needs to successfully navigate clinical trials and secure partnerships to achieve long-term growth, while also mitigating threats from competition and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Serina Therapeutics website
- SEC filings (e.g., 10-K, 10-Q)
- Company presentations
- Third-party market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data is based on publicly available information and may be subject to change. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Serina Therapeutics Inc
Exchange NYSE MKT | Headquaters Huntsville, AL, United States | ||
IPO Launch date 2018-11-29 | CEO & Director Mr. Steven A. Ledger | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://serinatherapeutics.com |
Full time employees 12 | Website https://serinatherapeutics.com | ||
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.